Delcath Systems, Inc. (DCTH) analyst actions
Rating and price-target actions on DCTH in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the DCTH overview →
3 measured DCTH analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts | Press release | -0.18% | +0.55% | |
| Delcath Systems Announces Investigator-Initiated CHOPIN Clinical Trial Meets Primary Endpoint | Press release | -0.17% | +8.35% | |
| Delcath Systems Announces Investigator-Initiated CHOPIN Phase 2 Trial Presentation at ESMO 2025 Congress | Press release | -0.73% | -4.84% |
Keep exploring
More DCTH: earnings → · SEC filings → · DCTH overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | 275 | 0.00% | 48% |
| Anika Therapeutics Inc. (ANIK) | 275 | +0.07% | 52% |
| Evolus, Inc. (EOLS) | 275 | +0.08% | 51% |
| LivaNova PLC - Ordinary Shares (LIVN) | 275 | +0.04% | 51% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.